Deutsche Bank AG Increases Position in MiMedx Group, Inc $MDXG

Key Points

• Deutsche Bank AG significantly increased its stake in MiMedx Group, boosting its holdings by 144.2% to a total of 321,296 shares, valued at approximately $2.44 million.
• Analysts have raised their ratings on MiMedx Group, with Wall Street Zen upgrading it from "hold" to "strong-buy" and Cantor Fitzgerald increasing the price target from $11 to $12.
• MiMedx Group reported earnings of $0.10 per share, exceeding analysts' expectations, alongside revenue of $98.61 million for the quarter.

Deutsche Bank AG raised its position in MiMedx Group, Inc (NASDAQ:MDXG - Free Report) by 144.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 321,296 shares of the company's stock after buying an additional 189,750 shares during the period. Deutsche Bank AG owned about 0.22% of MiMedx Group worth $2,442,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Paradigm Capital Management Inc. NY boosted its holdings in shares of MiMedx Group by 0.5% during the 4th quarter. Paradigm Capital Management Inc. NY now owns 4,686,231 shares of the company's stock worth $45,082,000 after purchasing an additional 22,131 shares during the last quarter. First Light Asset Management LLC acquired a new position in shares of MiMedx Group during the 4th quarter worth approximately $32,168,000. Dimensional Fund Advisors LP boosted its holdings in shares of MiMedx Group by 15.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,802,364 shares of the company's stock worth $17,338,000 after purchasing an additional 238,075 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of MiMedx Group by 11.4% during the 4th quarter. Northern Trust Corp now owns 1,199,970 shares of the company's stock worth $11,544,000 after purchasing an additional 123,205 shares during the last quarter. Finally, Harbor Capital Advisors Inc. boosted its holdings in shares of MiMedx Group by 4.2% during the 1st quarter. Harbor Capital Advisors Inc. now owns 1,043,676 shares of the company's stock worth $7,932,000 after purchasing an additional 42,288 shares during the last quarter. 79.15% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Cantor Fitzgerald boosted their target price on MiMedx Group from $11.00 to $12.00 and gave the stock an "overweight" rating in a report on Thursday, July 31st. Wall Street Zen upgraded MiMedx Group from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 2nd. One investment analyst has rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $12.00.

MiMedx Group Trading Up 1.1%

Shares of MDXG stock traded up $0.08 during trading on Tuesday, hitting $7.16. 371,021 shares of the stock traded hands, compared to its average volume of 807,524. The firm has a market capitalization of $1.06 billion, a P/E ratio of 34.10 and a beta of 1.79. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.39 and a quick ratio of 3.90. MiMedx Group, Inc has a 52-week low of $5.47 and a 52-week high of $10.14. The firm's fifty day moving average price is $6.70 and its 200-day moving average price is $7.06.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.04. The company had revenue of $98.61 million for the quarter, compared to analyst estimates of $90.79 million. MiMedx Group had a return on equity of 23.03% and a net margin of 8.84%. As a group, research analysts forecast that MiMedx Group, Inc will post 0.3 earnings per share for the current fiscal year.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.